Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleIEEE Spectrum

How Do You Define an AI Companion?

View original at spectrum.ieee.org
IEEE Spectrum - Technical Title: How Do You Define an AI Companion?…
Opening lines of the source · IEEE Spectrum · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Many people develop AI companionship inadvertently, not by purposefully seeking companionship but through repeated use of AI tools for other purposes

    80% confidence
  • Sophisticated robotic companion bodies become very expensive and therefore inaccessible to many people; toylike bodies are accessible but limiting

    80% confidence
  • Social relatedness is one of the three intrinsic psychological needs, and humans will seek it from any available source including AI if not otherwise met

    80% confidence
  • The rise of AI companionship resulted from a perfect storm of LLM maturation converging with post-COVID social isolation

    80% confidence
  • The field lacks longitudinal data to support causal claims linking AI companions to loneliness; studies show conflicting results — some show companions increase loneliness, others show they reduce it, and other work suggests loneliness precedes companion use

    80% confidence
  • Data privacy concerns around intimate data shared with company-owned AI agents are a very reasonable concern

    80% confidence
  • AI companionship is a connection between a human and a machine that is dyadic, sustained over time, positively valenced, and autotelic

    80% confidence
  • Following the collapse of the soulmate app, many users stated they would only trust AI companions they could run locally on their own computers

    80% confidence
  • Most scholars abandoned technological determinism long ago; communication sciences does not assume machines make people do things because humans have agency in technology interactions

    80% confidence
  • It is irresponsible to discount the lived experiences of people who get real benefits and deeply meaningful experiences from AI companions

    80% confidence
  • Causal claims about AI companions making users suicidal or causing them to abandon other humans are based on unfortunate but uncommon situations and lack longitudinal data support

    80% confidence
  • When Replika disabled its erotic roleplay module, users described their companions as having been lobotomized

    80% confidence
  • There appear to be two relational templates for AI companionship: purely autotelic appreciation and a hybrid autotelic-utilitarian pattern

    80% confidence
  • Embodied AI companions are limited by their physical body's capabilities, whereas digital-only AI allows users to explore fantastic scenarios impossible with physical entities

    80% confidence
  • Children's difficulty navigating boundaries between fiction and reality is a valid concern regarding AI companion interactions with minors

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com